Society for Maternal-Fetal Medicine Statement: Antihypertensive therapy for mild chronic hypertension in pregnancy–The Chronic Hypertension and Pregnancy trial - 20/07/22
Society for Maternal-Fetal Medicine; Publications Committee⁎
Abstract |
The recently published Chronic Hypertension and Pregnancy study provides important data to inform the management of mild chronic hypertension in pregnancy. The purpose of this statement is to review the results of this trial and provide guidance for the implementation of the study findings. Based on the available evidence, SMFM recommends treatment with antihypertensive therapy for mild chronic hypertension in pregnancy to a goal blood pressure of <140/90 mm Hg. Patients with treated chronic hypertension should continue established antihypertensive therapy during pregnancy or change to a regimen compatible with pregnancy to achieve this treatment goal.
Le texte complet de cet article est disponible en PDF.Key words : antihypertensive therapy, Chronic Hypertension and Pregnancy (CHAP) trial
| All authors and Committee members have filed a disclosure of interests delineating personal, professional, business, or other relevant financial or nonfinancial interests in relation to this publication. Any substantial conflicts of interest have been addressed through a process approved by the Society for Maternal-Fetal Medicine (SMFM) Board of Directors. SMFM has neither solicited nor accepted any commercial involvement in the specific content development of this publication. Members with direct involvement in related studies did not participate in the development or review of this statement. |
|
| This document has undergone an internal peer review through a multilevel committee process within SMFM. This review involves critique and feedback from the SMFM Publications and Document Review Committees and final approval by the SMFM Executive Committee. SMFM accepts sole responsibility for the document content. SMFM publications do not undergo editorial and peer review by the American Journal of Obstetrics & Gynecology. The SMFM Publications Committee reviews publications every 18 to 24 months and issues updates as needed. Further details regarding SMFM publications can be found at publications. |
|
| SMFM recognizes that obstetrical patients have diverse gender identities and is striving to use gender-inclusive language in all of its publications. SMFM will be using terms such as “pregnant person” or “pregnant individual” instead of “pregnant woman” and will use the singular pronoun “they.” When describing study populations used in research, SMFM will use the gender terminology reported by the study investigators. |
Vol 227 - N° 2
P. B24-B27 - août 2022 Retour au numéro
Article précédent
- Society for Maternal-Fetal Medicine Special Statement: Best-practice recommendations for ultrasound network connectivity
- Society for Maternal-Fetal Medicine (SMFM), Thomas Lee, Joanne Stone, Vanita Jain, Noa Avtalion, Jacqueline Wickersham, Joey Haddock, Mark Scott, Carol Grone, Diane Hibbs, Kelly S. Gibson, Helen Feltovich, Brian Iriye, David Lagrew, Clinical Informatics Committee
- Society for Maternal-Fetal Medicine Consult Series #61: Anticoagulation in pregnant patients with cardiac disease
- Society for Maternal-Fetal Medicine (SMFM), Luis D. Pacheco, George Saade, Vineet Shrivastava, Raj Shree, Uri Elkayam, Publications Committee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?